The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1442237
Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer
Provisionally accepted- 1 Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Anhui Province, China
- 2 Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China
Osimertinib, a third-generation inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, exhibits remarkable efficacy in prolonging the survival of patients with non-small cell lung cancer (NSCLC) carrying EGFR mutations, surpassing the efficacy of first- and second-generation EGFR tyrosine kinases. Nevertheless, the emergence of osimertinib resistance is inevitable, necessitating an investigation into the underlying mechanisms. Increasing evidence has revealed that non-coding RNAs (ncRNAs), including microRNAs, long ncRNAs, and circular RNAs, play a significant role in the development and progression of lung cancer. These ncRNAs regulate essential signaling pathways, offering a novel avenue for understanding the fundamental mechanisms of osimertinib resistance. Recent studies have reported the significant impact of ncRNAs on osimertinib resistance, achieved through various mechanisms that modulate treatment sensitivity. We provide a concise overview of the functions and underlying mechanisms of extensively researched ncRNAs in the development of osimertinib resistance and emphasize their potential clinical application in EGFR-mutated NSCLC resistant to osimertinib. Finally, we discuss the obstacles that must be addressed to effectively translate ncRNA-based approaches into clinical practice.
Keywords: Non-small cell lung cancer, EGFR, ncRNA, Osimertinib resistance, Mechanism
Received: 01 Jun 2024; Accepted: 23 Aug 2024.
Copyright: © 2024 Zeng, Gan, Yu, Hu, Deng, Yin and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Kelun Gan, Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Anhui Province, China
Yuanhang Yu, Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Anhui Province, China
Jianping Hu, Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Anhui Province, China
Qiao Deng, Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Anhui Province, China
Xi Gao, Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Anhui Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.